WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004028480) CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/028480    International Application No.:    PCT/US2003/031005
Publication Date: 08.04.2004 International Filing Date: 30.09.2003
Chapter 2 Demand Filed:    26.02.2004    
IPC:
A61K 31/549 (2006.01)
Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 1111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (US) (For All Designated States Except US).
VERKMAN, Alan [US/US]; (US) (For US Only).
MA, Tonghui [CN/US]; (US) (For US Only)
Inventors: VERKMAN, Alan; (US).
MA, Tonghui; (US)
Agent: FRANCIS, Carol, L.; Bozicevic, Field & Francis LLP, 1900 University Avenue, Suite 200, East Palo Alto, CA 94303 (US)
Priority Data:
10/262,573 30.09.2002 US
60/480,253 20.06.2003 US
Title (EN) CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN INHIBITORS AND USES THEREOF
(FR) INHIBITEURS DE PROTEINE REGULANT LA PERMEABILITE TRANSMEMBRANAIRE DE LA FIBROSE KYSTIQUE (CFTR) ET UITLISATIONS
Abstract: front page image
(EN)The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a thiazolidinone compound to a non-human animal in an amount sufficient to inhibit CFTR.
(FR)L'invention concerne des compositions, des préparations pharmaceutiques et des procédés permettant d'inhiber la protéine CFTR, utiles pour l'étude et le traitement des maladies dont la médiation est assurée par la protéine CFTR. Les compositions et les préparations pharmaceutiques peuvent comprendre un ou plusieurs composés thiazolidinone, et par ailleurs un ou plusieurs vecteurs, excipients et/ou adjuvants pharmaceutiquement acceptables. Les procédés consistent, selon certaines variantes, à administrer au patient soufrant d'une maladie ou d'une affection dont la médiation est assurée par la protéine CFTR une quantité efficace de composé thiazolidinone. Sous d'autres variantes, on décrit des procédés inhibant la protéine CFTR qui consistent à mettre en contact des cellules du patient avec une quantité efficace de composé thiazolidinone. L'invention concerne également un modèle animal non humain de maladie dont la médiation est assurée par la protéine CFTR, résultant de l'administration d'un composé thiazolidinone à un animal non humain, en quantité suffisante pour inhiber la protéine CFTR.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)